[{"id":"b467a2c6-7621-4f9d-a068-1886d5c9de0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02729298","created_at":"2021-01-18T13:21:39.360Z","updated_at":"2024-07-02T16:35:29.379Z","phase":"Phase 1","brief_title":"First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT02729298","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dubermatinib (TP-0903)"],"overall_status":"Completed","enrollment":" Enrollment 177","initiation":"Initiation: 12/14/2016","start_date":" 12/14/2016","primary_txt":" Primary completion: 06/29/2022","primary_completion_date":" 06/29/2022","study_txt":" Completion: 06/29/2022","study_completion_date":" 06/29/2022","last_update_posted":"2023-11-14"},{"id":"e65ca9a7-1045-4f86-8887-7faabd39cc38","acronym":"","url":"https://clinicaltrials.gov/study/NCT04518345","created_at":"2021-01-18T21:38:55.797Z","updated_at":"2024-07-02T16:35:56.436Z","phase":"Phase 1b/2","brief_title":"TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT04518345","lead_sponsor":"Uma Borate","biomarkers":" FLT3 • CD4","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • dubermatinib (TP-0903)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 11/05/2020","start_date":" 11/05/2020","primary_txt":" Primary completion: 10/13/2021","primary_completion_date":" 10/13/2021","study_txt":" Completion: 12/22/2021","study_completion_date":" 12/22/2021","last_update_posted":"2023-02-06"}]